bioAffinity Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIAF research report →
Price Chart
About the company
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer.
- CEO
- Maria Zannes
- IPO
- 2022
- Employees
- 57
- HQ
- San Antonio, TX, US
Get TickerSpark's AI analysis on BIAF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.37M
- P/E
- -0.03
- PEG
- -0.00
- P/S
- 1.88
- P/B
- 0.38
- EV/EBITDA
- -0.62
- Div Yield
- 0.00%
- Gross Margin
- -50.12%
- Op Margin
- -246.14%
- Net Margin
- -278.93%
- ROE
- -331.02%
- ROIC
- -251.26%
Latest fiscal year · YoY change
- Revenue
- $6.16M-34.2%
- Gross Profit
- $1.43M-57.7%
- Op Income
- $-10,572,508
- Net Income
- $-14,909,754-64.9%
- EPS
- $-129.90+61.5%
- OCF Growth
- -28.4%
- FCF Growth
- -27.9%
- 52W High
- $80.70
- 52W Low
- $1.63
- 50D MA
- $4.51
- 200D MA
- $18.06
- Beta
- -1.05
- RSI (14)
- 30
- Avg Volume
- 3.55M
No earnings-call transcripts are available for BIAF yet.
- Free Float
- 70.4%
- Shares Outstanding
- 6.28M
- Float Shares
- 4.42M
of shares held by institutions
21 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hrt Financial LP | 91.43K | ▲ 70.60K |
| Jane Street Group, LLC | 42.79K | ▲ 16.00K |
| Virtu Financial LLC | 16.74K | ▲ 5.63K |
| Blackrock, Inc. | 6.58K | ▼ 92.19K |
| Vanguard Capital Management LLC | 3.70K | ▼ 51.84K |
| Ubs Group AG | 3.10K | ▼ 1.10K |
| Vanguard Fiduciary Trust Co | 2.07K | ▼ 29.00K |
| Emc Capital Management | 2.00K | ▲ 2.00K |
| Allworth Financial LP | 666 | ▲ 666 |
| Tower Research Capital LLC (Trc) | 318 | ▼ 6.16K |
| Robinhood Markets, Inc. | 38 | ▲ 38 |
| Russell Investments Group, Ltd. | 1 | ▲ 1 |
Held by 7 ETFs
Biggest fund positions in BIAF by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 29, 26 | HRT FINANCIAL LP | buy | 8,894 |
| Sep 29, 26 | HRT FINANCIAL LP | buy | 13,840 |
| Sep 29, 26 | HRT FINANCIAL LP | sell | 18,627 |
| Sep 29, 26 | HRT FINANCIAL LP | sell | 2,201 |
| Sep 24, 26 | HRT FINANCIAL LP | sell | 27,246 |
| Sep 24, 26 | HRT FINANCIAL LP | buy | 30,065 |
| Sep 23, 26 | HRT FINANCIAL LP | sell | 11,129 |
| Sep 23, 26 | HRT FINANCIAL LP | buy | 11,002 |
| Sep 23, 26 | HRT FINANCIAL LP | buy | 7,509 |
| Sep 23, 26 | HRT FINANCIAL LP | sell | 10,859 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIAF coverage
Recent articles, reports, and earnings notes.
No research on BIAF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIAF report →BIAF Stock Dips Post Q3 Earnings Despite Rising Test Demand, Sales Down
zacks.com · Nov 13
bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test
businesswire.com · Nov 11
bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization
businesswire.com · Nov 6
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
businesswire.com · Oct 29
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
prnewswire.com · Oct 9
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
businesswire.com · Oct 9
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
prnewswire.com · Oct 8
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
businesswire.com · Oct 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.